IL179785A - Method for freezing pluripotent stem cells - Google Patents
Method for freezing pluripotent stem cellsInfo
- Publication number
- IL179785A IL179785A IL179785A IL17978506A IL179785A IL 179785 A IL179785 A IL 179785A IL 179785 A IL179785 A IL 179785A IL 17978506 A IL17978506 A IL 17978506A IL 179785 A IL179785 A IL 179785A
- Authority
- IL
- Israel
- Prior art keywords
- cell
- temperature
- cells
- cell suspension
- thawing
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 113
- 230000008014 freezing Effects 0.000 title claims description 49
- 238000007710 freezing Methods 0.000 title claims description 46
- 210000000130 stem cell Anatomy 0.000 title claims description 37
- 210000004027 cell Anatomy 0.000 claims description 223
- 239000006285 cell suspension Substances 0.000 claims description 46
- 230000006910 ice nucleation Effects 0.000 claims description 31
- 238000010257 thawing Methods 0.000 claims description 28
- 238000003860 storage Methods 0.000 claims description 23
- 238000001816 cooling Methods 0.000 claims description 15
- 230000004913 activation Effects 0.000 claims description 12
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 11
- 230000035899 viability Effects 0.000 claims description 11
- 230000012010 growth Effects 0.000 claims description 10
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 239000002577 cryoprotective agent Substances 0.000 claims description 8
- 230000007774 longterm Effects 0.000 claims description 8
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 230000018044 dehydration Effects 0.000 claims description 5
- 238000006297 dehydration reaction Methods 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 210000003061 neural cell Anatomy 0.000 claims description 3
- 210000005132 reproductive cell Anatomy 0.000 claims description 3
- 210000004927 skin cell Anatomy 0.000 claims description 3
- 210000001612 chondrocyte Anatomy 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 210000000442 hair follicle cell Anatomy 0.000 claims description 2
- 210000003494 hepatocyte Anatomy 0.000 claims description 2
- 210000004409 osteocyte Anatomy 0.000 claims description 2
- 238000007711 solidification Methods 0.000 claims description 2
- 230000008023 solidification Effects 0.000 claims description 2
- 101100011750 Mus musculus Hsp90b1 gene Proteins 0.000 claims 2
- 101150117196 tra-1 gene Proteins 0.000 claims 2
- 238000005138 cryopreservation Methods 0.000 description 43
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 42
- 239000010902 straw Substances 0.000 description 39
- 239000007788 liquid Substances 0.000 description 23
- 229910052757 nitrogen Inorganic materials 0.000 description 21
- 238000011084 recovery Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 101100016889 Rattus norvegicus Hes2 gene Proteins 0.000 description 13
- 230000004069 differentiation Effects 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 8
- 102000029816 Collagenase Human genes 0.000 description 7
- 108060005980 Collagenase Proteins 0.000 description 7
- 101150094793 Hes3 gene Proteins 0.000 description 7
- 229960002424 collagenase Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 6
- 239000012595 freezing medium Substances 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000004017 vitrification Methods 0.000 description 5
- 210000004102 animal cell Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000011194 good manufacturing practice Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000001342 constant potential amperometry Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002242 embryoid body Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 241000277331 Salmonidae Species 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000959 cryoprotective effect Effects 0.000 description 2
- 230000002559 cytogenic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000275 quality assurance Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100519293 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pdx-1 gene Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 229910001610 cryolite Inorganic materials 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000004670 early embryonic cell Anatomy 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000013411 master cell bank Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000000718 radiation-protective agent Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/16—Physical preservation processes
- A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004902933A AU2004902933A0 (en) | 2004-06-02 | Cell preservation method | |
| AU2005902548A AU2005902548A0 (en) | 2005-05-18 | Cell preservation method 2 | |
| PCT/AU2005/000783 WO2005118785A1 (en) | 2004-06-02 | 2005-06-02 | Cell preservation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL179785A0 IL179785A0 (en) | 2007-05-15 |
| IL179785A true IL179785A (en) | 2014-09-30 |
Family
ID=35462905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL179785A IL179785A (en) | 2004-06-02 | 2006-12-03 | Method for freezing pluripotent stem cells |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9714412B2 (https=) |
| EP (1) | EP1765986A4 (https=) |
| JP (1) | JP2008501320A (https=) |
| CA (1) | CA2569485C (https=) |
| GB (1) | GB2429717B (https=) |
| IL (1) | IL179785A (https=) |
| WO (1) | WO2005118785A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008501320A (ja) | 2004-06-02 | 2008-01-24 | イーエス・セル・インターナショナル・プライヴェート・リミテッド | 細胞保存方法 |
| US8794013B2 (en) * | 2006-02-10 | 2014-08-05 | Praxair Technology, Inc. | Method and system for nucleation control in a controlled rate freezer (CRF) |
| GB0605450D0 (en) * | 2006-03-17 | 2006-04-26 | Intercytex Ltd | Cell co-culture |
| CA2619547C (en) | 2007-02-06 | 2016-05-17 | Smith International, Inc. | Polycrystalline diamond constructions having improved thermal stability |
| US7942219B2 (en) | 2007-03-21 | 2011-05-17 | Smith International, Inc. | Polycrystalline diamond constructions having improved thermal stability |
| GB0719751D0 (en) | 2007-10-10 | 2007-11-21 | Antoxis Ltd | In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells |
| US9297211B2 (en) | 2007-12-17 | 2016-03-29 | Smith International, Inc. | Polycrystalline diamond construction with controlled gradient metal content |
| CA2760175C (en) * | 2009-04-29 | 2018-05-29 | Biolife Solutions, Inc. | Apparatuses and compositions for cryopreservation of cellular monolayers |
| ITTO20090797A1 (it) * | 2009-10-21 | 2011-04-22 | Lucia Maria Moriondo | Metodo e soluzione per la crioconservazione di embrioni umani |
| JP2013519723A (ja) | 2010-02-19 | 2013-05-30 | カディラ ファーマシューティカルズ リミテッド | 実質的に保持された免疫原性を有する死細胞の薬学的組成物 |
| GB201017315D0 (en) | 2010-10-13 | 2010-11-24 | Antoxis Ltd | Compound |
| WO2013096710A1 (en) * | 2011-12-21 | 2013-06-27 | Biocision, Llc | Method and devices for cryopreservation of biomaterials |
| WO2014037807A2 (en) * | 2012-09-07 | 2014-03-13 | Biolamina Ab | Stem cell bank |
| GB201222241D0 (en) * | 2012-12-11 | 2013-01-23 | Morris George J | Control of ice formation |
| FR3035407B1 (fr) | 2015-04-23 | 2022-06-17 | Francais Du Sang Ets | Procede de conservation de cellules, tissus ou organes en hypothermie |
| US20180369287A1 (en) | 2015-10-08 | 2018-12-27 | Neurona Therapeutics Inc. | Neural precursor cell populations and uses thereof |
| US10531657B2 (en) | 2015-12-07 | 2020-01-14 | Coopersurgical, Inc. | Low temperature specimen carriers and related methods |
| EP3407844A4 (en) * | 2016-01-29 | 2019-10-16 | Qool Therapeutics, Inc. | AEROSOLISATION OF STEM CELLS OR STEM CELL DERIVATIVES FOR PULMONARY ADMINISTRATION |
| EP3455346A1 (en) | 2016-05-12 | 2019-03-20 | Erasmus University Medical Center Rotterdam | A method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium |
| NL2019517B1 (en) | 2017-09-08 | 2019-03-19 | Univ Erasmus Med Ct Rotterdam | New therapy for Pompe disease |
| AU2020387259A1 (en) * | 2019-11-20 | 2022-06-09 | Kyoto University | Method for freezing neural cells |
| JP2024503726A (ja) * | 2021-01-19 | 2024-01-26 | ギャラント・ペット，インコーポレイテッド | 臨床応用のために生殖組織由来細胞の収量および生存率を最適化する方法 |
| US12471592B2 (en) | 2021-08-18 | 2025-11-18 | Reelabs Private Limited | Cytoprotective compositions for short-term cells storage and transportation without cryopreservation and deep freezing |
| CN116602292B (zh) * | 2023-05-29 | 2026-01-02 | 广西壮族自治区水牛研究所 | 一种利用冻精管冻存生物细胞的方法 |
| WO2025160465A1 (en) | 2024-01-26 | 2025-07-31 | Celularity Inc. | A method of treating signs or symptoms of the aging process |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8611894D0 (en) * | 1986-05-15 | 1986-06-25 | Cell Systems Ltd | Biological cryo-protection |
| US5891617A (en) | 1993-09-15 | 1999-04-06 | Organogenesis Inc. | Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing |
| GB2330516A (en) | 1997-10-22 | 1999-04-28 | Elizabeth Acton | Cryopreservation of cell suspensions |
| WO2001068815A1 (en) | 2000-03-14 | 2001-09-20 | Es Cell International Pte Ltd | Embryonic stem cells and neural progenitor cells derived therefrom |
| CN1668733A (zh) * | 2002-05-30 | 2005-09-14 | 细胞基因公司 | 利用jnk或mkk抑制剂调节细胞分化并治疗骨髓增生异常和脊髓发育不良综合症的方法 |
| WO2004010780A2 (en) | 2002-07-30 | 2004-02-05 | General Biotechnology, Llc | Innocuous intracellular ice |
| JP2006525006A (ja) | 2003-05-08 | 2006-11-09 | セルアーティス アーベー | 閉塞ストローガラス化方法を利用するヒト胚盤胞由来幹細胞の低温保存法 |
| JP2008501320A (ja) | 2004-06-02 | 2008-01-24 | イーエス・セル・インターナショナル・プライヴェート・リミテッド | 細胞保存方法 |
| US7811819B2 (en) | 2005-05-31 | 2010-10-12 | The University Of Washington | Cryopreservation of primate embryonic stem cells |
-
2005
- 2005-06-02 JP JP2007513616A patent/JP2008501320A/ja active Pending
- 2005-06-02 EP EP05744902A patent/EP1765986A4/en not_active Ceased
- 2005-06-02 WO PCT/AU2005/000783 patent/WO2005118785A1/en not_active Ceased
- 2005-06-02 US US11/628,443 patent/US9714412B2/en not_active Expired - Fee Related
- 2005-06-02 CA CA2569485A patent/CA2569485C/en not_active Expired - Fee Related
- 2005-06-02 GB GB0625461A patent/GB2429717B/en not_active Expired - Fee Related
-
2006
- 2006-12-03 IL IL179785A patent/IL179785A/en active IP Right Grant
-
2017
- 2017-06-08 US US15/617,892 patent/US10472606B2/en not_active Expired - Fee Related
-
2019
- 2019-10-03 US US16/591,985 patent/US20200208104A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL179785A0 (en) | 2007-05-15 |
| CA2569485A1 (en) | 2005-12-15 |
| CA2569485C (en) | 2015-08-18 |
| US20200208104A1 (en) | 2020-07-02 |
| GB2429717A (en) | 2007-03-07 |
| WO2005118785A1 (en) | 2005-12-15 |
| EP1765986A1 (en) | 2007-03-28 |
| US20080057040A1 (en) | 2008-03-06 |
| JP2008501320A (ja) | 2008-01-24 |
| GB0625461D0 (en) | 2007-02-07 |
| EP1765986A4 (en) | 2007-11-07 |
| US20170275588A1 (en) | 2017-09-28 |
| US10472606B2 (en) | 2019-11-12 |
| GB2429717B (en) | 2009-04-08 |
| US9714412B2 (en) | 2017-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200208104A1 (en) | Cell Preservation Method for Pluripotent Stem Cells | |
| Ji et al. | Cryopreservation of adherent human embryonic stem cells | |
| Hunt | Cryopreservation of human stem cells for clinical application: a review | |
| AU2017377309B9 (en) | Mammalian cell cryopreservation liquid | |
| RU2563518C2 (ru) | Улучшенная клеточная композиция и способы ее получения | |
| AU2009228141A1 (en) | Mehtod, system, and apparatus for hypothermic collection, storage, transport and banking of birth tissue | |
| WO2004098285A2 (en) | Cryopreservation of human blastocyst-derived stem cells by use of a closed straw vitrification method | |
| Marquez-Curtis et al. | Expansion and cryopreservation of porcine and human corneal endothelial cells | |
| Martín-Ibáñez et al. | Cryopreservation of human pluripotent stem cells: are we going in the right direction | |
| JP6487552B2 (ja) | 植物由来組換えヒト血清アルブミン及び植物性ペプチドを有効成分として含有する細胞保存用組成物 | |
| KR20120126634A (ko) | 조직 보관 방법 | |
| Dash et al. | Use of the non-toxic cryoprotectant trehalose enhances recovery and function of fish embryonic stem cells following cryogenic storage | |
| Zhang et al. | Cryopreservation of human induced pluripotent stem cells by using a new CryoLogic vitrification method | |
| AU2005250053B2 (en) | Cell preservation method | |
| Nishigaki et al. | Cryopreservation of primate embryonic stem cells with chemically-defined solution without Me2SO | |
| WO2001092481A1 (en) | Method of preparing small hepatocytes preservable in freeze-dried state and method of preserving the same in freeze-dried state | |
| JP6851602B2 (ja) | ヒト幹細胞の保存液、ヒト幹細胞懸濁液およびヒト幹細胞の保存方法 | |
| Ferreira | Cryopreservation and Thawing Protocol of Mesenchymal Stem Cells for use in Veterinary Medicine Cell Therapy | |
| WO2023175930A1 (ja) | 卵子成熟促進剤及びその用途 | |
| Nawroth et al. | Vitrification of ovarian tissue | |
| Talwar et al. | 28 Human Embryonic Stem Cells | |
| Nawroth et al. | 11A Vitrification of ovarian tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB20 | Patent renewed for 20 years |